Walvax Biotechnology Co., Ltd.
300142
Kedudukan dalam Saham
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Harga Saham
$1.87
Modal Pasaran
$2.98B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
14.73%
Negara
CN
Perdagangan Walvax Biotechnology Co., Ltd. (300142)
Kategori
Healthcare
Hasil untuk Walvax Biotechnology Co., Ltd. (300142)
Hasil pada Jun 2026 TTM: $313.01M
Menurut laporan kewangan terkini daripada Walvax Biotechnology Co., Ltd., hasil semasa syarikat (TTM) ialah $313.01M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $386.55M penurunan berbanding hasil pada tahun 2023 iaitu $581.16M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Walvax Biotechnology Co., Ltd. dari 2007 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $313.01M | -9.14% |
| 2025 | $344.50M | -10.88% |
| 2024 | $386.55M | -33.49% |
| 2023 | $581.16M | -21.19% |
| 2022 | $737.39M | 35.35% |
| 2021 | $544.82M | 21.10% |
| 2020 | $449.89M | 179.41% |
| 2019 | $161.02M | 26.68% |
| 2018 | $127.11M | 23.75% |
| 2017 | $102.71M | 20.66% |
| 2016 | $85.12M | -45.05% |
| 2015 | $154.92M | 33.46% |
| 2014 | $116.08M | 20.76% |
| 2013 | $96.13M | 11.51% |
| 2012 | $86.20M | 15.58% |
| 2011 | $74.58M | 37.20% |
| 2010 | $54.36M | 55.20% |
| 2009 | $35.03M | 29.85% |
| 2008 | $26.97M | 52.25% |
| 2007 | $17.72M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $23.54B | 7,419.13% |
DE
|
|
| $23.73B | 7,482.90% |
DE
|
|
| $29.24B | 9,241.55% |
JP
|
|
| $5.85B | 1,768.57% |
CH
|
|
| $6.34B | 1,926.24% |
IN
|
